Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$3.33
-0.06 (-1.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $691.7M · quality 77.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.4B
P/E
27.8x
↑EV/EBITDA
6.9x
↓ROE
6.4%
↑Gross Margin
26.0%
↓Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.0%
FCF CAGR
-18.5%
FCF margin
1.8%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.96B · net income $361.6M · FCF $288.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.96B | $15.96B | $16.18B | $15.46B | $13.81B |
| Net Income | $361.6M | $361.6M | $628.8M | $395.3M | $465.2M |
| EBITDA | $924.4M | $924.4M | $1.22B | $1.01B | $1.10B |
| EPS | 0.14 | 0.14 | 0.25 | 0.16 | 0.18 |
| Gross Margin | 26.0% | 26.0% | 28.2% | 26.2% | 24.7% |
| Operating Margin | 4.6% | 4.6% | 6.0% | 4.9% | 4.8% |
| Net Margin | 2.3% | 2.3% | 3.9% | 2.6% | 3.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.33 | 0.39 | 0.50 |
| Current Ratio | 1.45 | 1.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $288.7M | $288.7M | $691.7M | $863.1M | $532.4M |
| Returns | |||||
| ROE | 6.4% | 6.4% | 11.8% | 8.4% | 10.7% |
| Valuation | |||||
| P/E | 27.75 | 27.75 | 15.84 | 21.00 | 17.17 |
| EV/EBITDA | 6.93 | 6.93 | 6.62 | 7.03 | 7.03 |
| P/B | 1.51 | 1.51 | 1.86 | 1.76 | 1.85 |
| Growth & Yield | |||||
| Revenue Growth | -1.3% | -1.3% | 4.7% | 11.9% | — |
| EPS Growth | -44.0% | -44.0% | 56.3% | -11.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
28.3%
EPS terminal req.
$0.30
Spread vs growth
-72.3%
5Y implied EPS CAGR
20.6%
EPS terminal req.
$0.36
Spread vs growth
-64.6%
10Y implied EPS CAGR
15.2%
EPS terminal req.
$0.58
Spread vs growth
-59.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.5%
Start / end P/E
15.4x → 23.8x
EPS bridge
0.25 → 0.14
Residual
-24.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.